Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy
Open-label, no control groupHumans
- Design
- Open-label, no control group
- Subjects
- 20 patients with multiple myeloma and painful neuropathy from thalidomide and bortezomib
- Dose used in the study
- PEA 300 mg twice daily
- Duration
- 2 months
- What was measured
- Pain, warmth thresholds, and motor and sensory nerve conduction and laser-evoked potentials measured by blinded examiners.
What the authors reported
Pain and all neurophysiological measures of myelinated A-alpha, A-beta and A-delta fibres improved (p < 0.05), though none returned to normal. Warmth thresholds, which reflect unmyelinated fibres, did not change.
Limits of this study
No control group; the authors note a placebo effect could explain the pain change. 20 patients. The objective nerve measures were assessed blind, which is the study's strength.
Source
PubMed 22229320 · doi:10.2174/187152711799219307
Entry checked against the abstract, supplied by Devlin on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.